Showing results (331-340 of 1,028) with videos related to

Sort By:
Pageof 103
The Lancet. Respiratory Medicine|November 29, 2018
Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the futureAndrew J Boyle, Michael C Sklar, James J McNamee, et al.
The Lancet. Respiratory Medicine|January 27, 2020
Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association studyBeatriz Guillen-Guio, Jose M Lorenzo-Salazar, Shwu-Fan Ma, et al.
The Lancet. Respiratory Medicine|April 4, 2020
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trialYasuyuki Kakihana, Osamu Nishida, Takumi Taniguchi, et al.
The Lancet. Respiratory Medicine|August 31, 2020
Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational studyPratik Sinha, Carolyn S Calfee, Shiney Cherian, et al.
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
The Lancet. Respiratory Medicine|July 18, 2025
Evaluating the generalisability of formulas used to set tidal volumes in mechanically ventilated patients: an observational, multicohort, retrospective studyAartik Sarma, Kathryn M Sullivan, Aaron D Baugh, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine|July 12, 2025
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trialStephanie A Christenson, Nicola A Hanania, Surya P Bhatt, et al.
The Lancet. Respiratory Medicine|June 2, 2025
Extracorporeal cardiopulmonary resuscitation for refractory cardiac arrestAlexander Supady, Jan Bělohlávek, Alain Combes, et al.
The Lancet. Respiratory Medicine|June 23, 2025
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trialYuankai Shi, Lin Wu, Yinghua Ji, et al.
Pageof 103